Head to Head Contrast: ImageneBio (NASDAQ:IMA) & Stoke Therapeutics (NASDAQ:STOK)

ImageneBio (NASDAQ:IMA) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Earnings and Valuation

This table compares ImageneBio and Stoke Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImageneBio	N/A	N/A	-$45.35 million	($4.58)	-0.92
Stoke Therapeutics	$184.42 million	8.76	-$6.89 million	($3.34)	-7.50

Stoke Therapeutics has higher revenue and earnings than ImageneBio. Stoke Therapeutics is trading at a lower price-to-earnings ratio than ImageneBio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for ImageneBio and Stoke Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImageneBio	2	0	1	0	1.67
Stoke Therapeutics	1	0	10	0	2.82

ImageneBio currently has a consensus target price of $28.00, indicating a potential upside of 563.51%. Stoke Therapeutics has a consensus target price of $44.25, indicating a potential upside of 76.72%. Given ImageneBio’s higher probable upside, research analysts plainly believe ImageneBio is more favorable than Stoke Therapeutics.

Risk and Volatility

ImageneBio has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Profitability

This table compares ImageneBio and Stoke Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ImageneBio	N/A	-38.99%	-34.84%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Insider & Institutional Ownership

75.0% of ImageneBio shares are held by institutional investors. 2.2% of ImageneBio shares are held by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Stoke Therapeutics beats ImageneBio on 7 of the 13 factors compared between the two stocks.

About ImageneBio

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.